City of Hope | Strategic Alliance Partners

February 07, 2023

A detailed look at how to select the appropriate BTK inhibitor to treat patients with MCL and the potential role of the non-covalent BTK inhibitor pirtobrutinib in MCL.

February 01, 2023

Marwan G. Fakih, MD, discusses a comparative analysis of the tumor microenvironment in primary tumors vs metastatic tissue in patients with microsatellite stable metastatic colorectal cancer.

January 31, 2023

Experts in hematologic malignancies review the role of BTK inhibitors and other therapies in patients with relapsed/refractory mantle cell lymphoma.

January 31, 2023

A panel of experts in hematologic malignancies discuss the SHINE study, which looked at ibrutinib with bendamustine and rituximab in elderly patients with MCL.

January 27, 2023

Tycel Phillips, MD, discusses the significance of the FDA approval of pirtobrutinib in mantle cell lymphoma.

January 17, 2023

Amandeep Salhotra, MD, provides insight on the data with Orca-Q shared during the 2022 ASH Annual Meeting.

January 12, 2023

Tanya Dorff, MD, discusses the exploration of triplet combination therapies in patients with metastatic hormone-sensitive prostate cancer.

January 12, 2023

because of the differences between the characteristics of research subjects and individuals routinely cared for outside the confines of a clinical trial, appropriately designed examinations of “real-world” populations may provide a more relevant picture of the actual influence of a particular therapeutic intervention.

January 10, 2023

Tanya Dorff, MD, discusses the investigation of PARP inhibitors in metastatic castration-resistant prostate cancer.

January 10, 2023

Tanya B. Dorff, MD, highlights improvements in the current treatment paradigm for other genitourinary cancers and spotlights efforts being made to expand the role of immunotherapy and targeted therapy combinations.

January 05, 2023

Joseph Alvarnas, MD, discusses the importance of access to CAR T-cell therapy in cancer care.

January 05, 2023

Sanjeet Singh Dadwal, MD, discusses the investigation of posoleucel as a prevention strategy for infections in patients following an allogenic hematopoietic cell transplant.

January 04, 2023

Tanya Dorff, MD, discusses remaining questions regarding sequencing in metastatic renal cell carcinoma.

December 21, 2022

Overall survival is a critically relevant end point in randomized oncology clinical trials, but its interpretation is often not as straightforward as some may wish to acknowledge.

December 11, 2022

The combination of selinexor and ruxolitinib significantly reduced spleen volume and total symptom score while achieving hemoglobin stabilization in an open-label dose-escalation/dose-expansion, phase 1 study of patients with treatment-naïve myelofibrosis.

December 11, 2022

Tycel Phillips, MD, MPH, discusses the investigation of glofitamab monotherapy in relapsed/refractory mantle cell lymphoma.

December 06, 2022

Chemotherapy prior to treatment with endocrine therapy could increase the risk of cancer-related cognitive impairment compared with endocrine therapy alone in women with breast cancer, irrespective of menopausal status.

November 29, 2022

Several articles in a recent issue of the high-impact journal Science highlight areas of concern in the scientific community that may have detrimental effects on communications regarding the human papillomavirus vaccination as a cancer prevention strategy.

November 22, 2022

Murali Janakiram, MD, MS, discusses future targets and research strategies for CAR T-cell therapy in multiple myeloma.

November 14, 2022

A core component of any type of therapeutic research is to enhance clinical benefit.